Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rinogermina
- Development stage
- Unknown
- Lead developer
- DMG Italia
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intranasal
01
Overview
Rinogermina is a topical nasal probiotic spray composed of two specific live bacterial strains: *Streptococcus salivarius* 24SMB and *Streptococcus oralis* 89a. It is designed to restore the natural nasopharyngeal microbiota and establish a biological barrier against pathogenic bacteria. The mechanism of action involves competitive exclusion for adhesion sites on the nasal mucosa and the production of bacteriocin-like inhibitory substances (BLIS) that antagonize the growth of pathobionts such as *Staphylococcus aureus*, *Moraxella catarrhalis*, and *Haemophilus influenzae*. Rinogermina is primarily used to manage and prevent recurrent upper respiratory tract infections, including chronic adenoiditis and otitis media, by reducing local inflammation and mechanical obstruction caused by hypertrophic adenoids. It is often classified as a medical device or a live biotherapeutic product in various regulatory jurisdictions.
- Brand names
- Rinogermina
- Other names
- S. salivarius 24SMB + S. oralis 89aStreptococcus salivarius 24SMB + Streptococcus oralis 89aS. salivarius 24SMBc + S. oralis 89a
Beyond the preview
Go deeper on Rinogermina.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rinogermina.